Sage Therapeutics Restructures to Prioritize ZURZUVAE® Launch and Streamline Development Pipeline
Sage Therapeutics, Inc. (Nasdaq: SAGE) has unveiled a strategic reorganization initiative aimed at prioritizing the commercialization of ZURZUVAE® for postpartum depression while sharpening its focus on pipeline development, including the upcoming clinical study for dalzanemdor in Huntington’s Disease, slated for…